Philip Morris International Inc Common Stock (PM)
Stock · NYSE · Health Care
$191.89as of 8/28/2026
Price chart
Open in TradingViewActive signals
No technical signal is currently active for this symbol.
About PM
Philip Morris International Inc. operates as a tobacco company. The company offers cigarettes and smoke-free products, including heat-not-burn, e-vapor, and oral nicotine products under the IQOS, VEEV, and ZYN brands; and consumer accessories, such as lighters and matches. It also offers wellness products. The company was incorporated in 1987 and is headquartered in Stamford, Connecticut.
- Sector
- Health Care
- Industry
- Medicinal Chemicals and Botanical Products
- Employees
- 84,900
- Website
- www.pmi.com
Fundamentals
- 1-day range
- $187.69$191.07
- Market cap
- $292.10B
- P/E (trailing)
- 26.12
- P/E (forward)
- 20.77
- EPS (trailing)
- $7.29
- Dividend yield
- 3.11%
- Beta
- 0.40
- Avg. volume
- 4.95M
- Ex-dividend date
- June 25, 2026
- Dividend pay date
- July 20, 2026
How Philip Morris International Inc Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 6, 2026 · via SEC EDGAR / Finnhub
Forecasts
15 analyst ratings
Philip Morris International Inc Common Stock Competitors
Chosen by industry and closest market cap.
- PMPhilip Morris International Inc Common Stock$191.89▲ 0.74%Market cap $292.10BP/E 26.12$142.11$207.76
- BTIBritish American Tobacco Industries p.l.c. Common Stock ADR$56.12▼ 0.28%Market cap $129.12BP/E 13.89$3,677$5,004
- MOAltria Group Inc.$68.67▲ 1.47%Market cap $113.98BP/E 13.75$54.7$77.06
- DFTXDefinium Therapeutics Inc. Common Shares$41▼ 6.44%Market cap $4.56BP/E —$8.7$49.7
- RLXRLX Technology Inc. American Depositary Shares each representing the right to receive one (1) Class A ordinary share$1.83▲ 1.67%Market cap $3.08BP/E 16.68$1.76$2.84
- RGCRegencell Bioscience Holdings Limited Ordinary Shares$5.52▼ 0.09%Market cap $3.03BP/E —$4.51$69
- TRLVTrulieve Cannabis Corp. Subordinate Voting Shares$11.82▲ 7.16%Market cap $1.65BP/E —$7.82$12.3
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PM Philip Morris International Inc Common Stock | $292.10B | 26.12 | $191.89 | ▲ 0.74% | $142.11$207.76 |
| BTI British American Tobacco Industries p.l.c. Common Stock ADR | $129.12B | 13.89 | $56.12 | ▼ 0.28% | $3,677$5,004 |
| MO Altria Group Inc. | $113.98B | 13.75 | $68.67 | ▲ 1.47% | $54.7$77.06 |
| DFTX Definium Therapeutics Inc. Common Shares | $4.56B | — | $41 | ▼ 6.44% | $8.7$49.7 |
| RLX RLX Technology Inc. American Depositary Shares each representing the right to receive one (1) Class A ordinary share | $3.08B | 16.68 | $1.83 | ▲ 1.67% | $1.76$2.84 |
| RGC Regencell Bioscience Holdings Limited Ordinary Shares | $3.03B | — | $5.52 | ▼ 0.09% | $4.51$69 |
| TRLV Trulieve Cannabis Corp. Subordinate Voting Shares | $1.65B | — | $11.82 | ▲ 7.16% | $7.82$12.3 |
P/E shows — for peers not currently carrying a live signal of their own.
Institutional Ownership
March 31, 2026
- Total shares held
- 1.21B
- Total value held
- $193.28B
- Institutional holders
- 2831
- Unknown133.45M
- Unknown107.60M
- Unknown101.16M
- Unknown79.82M
- Unknown72.76M
- Unknown55.03M
- Unknown50.11M
- Unknown44.77M
- Unknown38.46M
- Unknown24.41M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedSynthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
August 30, 2026
Philip Morris in focus as Altria manufacturing deal and ZYN Ultra news surface. Recent coverage of Philip Morris has centered on a new manufacturing agreement with Altria and on the FDA's authorization of ZYN Ultra nicotine pouches, which add to the company's smoke-free product line. One article frames Philip Morris as a high-growth smoke-free story that carries a premium valuation, while another asks whether strong quarterly results and the new pouch authorization should matter to those tracking the stock. The context here is that smoke-free products are increasingly central to how the company is being discussed in the news, even as it continues to pay a dividend yield above 3% on a trailing P/E near 26.